| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Leucovorin (Folinic acid), the active metabolite of folic acid, is primarily used as the calcium salt form of a folic acid antagonist, which prevents the conversion of folic acid to folinic acid, as an antidote or rescue agent. Methotrexate (MTX) and pyrimethamine's toxic effects are lessened by this medication. It can also be used to treat anemia caused by a folate deficiency, methanol poisoning, and colorectal cancer when combined with 5-fluorouracil.
| Targets |
Thymidylate Synthase
|
|---|---|
| ln Vitro |
The percentage of aberrant cells (Abs) and micronucleated binucleated cells (MNBN) increased concentration-dependently when methotrexate (MTX) was used alone. The nuclear division index (NDI) falls as MTX concentration rises. Similarly, in all experiments, the addition of 50 μg/mL leucovorin dramatically decreased the percentages of MNBN (40-68%) and Abs (36-77%). Additionally, at 5 μg/mL leucovorin, inhibitory effects were noted (12% to 54% for MNBN and 20% to 61% for Abs) [1].
|
| ln Vivo |
Leucovorin (7.0 mg/kg; i.p.; every other day; for 3 weeks; Balb/c Juvenile Solution) medication is administered after methotrexate (MTX) and seems to reverse the growth inhibition of MTX (Long-Term Give attention to MTX
Fed rabbits atherosclerosis progresses slowly when given dextrapril (5–20 mg/kg) [2]. Delapril (1-2 mg/kg, po, once daily for 5 weeks) When studying hypertension in an animal model: Fed rabbits cholesterol [2]
|
| Animal Protocol |
Animal/Disease Models: 24 3weeks old Balb/c young growing male mice (11.88±0.25 g) [2]
Doses: 7.0 mg/kg Route of Administration: intraperitoneal (ip) injection; every other day; for 3 weeks Experimental Results: After MTX administration appears to reverse this growth inhibition. |
| References |
[1]. Keshava, C., et al., Inhibition of methotrexate-induced chromosomal damage by folinic acid in V79 cells. Mutat Res, 1998. 397(2): p. 221-8.
[2]. Iqbal MP, et al. Effect of methotrexate and folinic acid on skeletal growth in mice. Acta Paediatr. 2003 Dec;92(12):1438-44. |
| Molecular Formula |
C20H23N7O7
|
|---|---|
| Molecular Weight |
473.446
|
| Exact Mass |
473.1659
|
| Elemental Analysis |
C, 50.74; H, 4.90; N, 20.71; O, 23.65
|
| CAS # |
58-05-9
|
| Related CAS # |
Folinic acid calcium;1492-18-8;Folinic acid calcium salt pentahydrate;6035-45-6;Folinic acid disodium;163254-40-8;Folinic acid calcium hydrate;1097832-14-8;Folinic acid-d4 calcium hydrate
|
| Appearance |
Solid powder
|
| SMILES |
C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
|
| InChi Key |
VVIAGPKUTFNRDU-ABLWVSNPSA-N
|
| InChi Code |
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
|
| Chemical Name |
(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
|
| Synonyms |
Leucovorin; Folinic acid; HSDB-6544; HSDB6544; HSDB 6544
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 95~250 mg/mL (200.7~528.1 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1122 mL | 10.5608 mL | 21.1216 mL | |
| 5 mM | 0.4224 mL | 2.1122 mL | 4.2243 mL | |
| 10 mM | 0.2112 mL | 1.0561 mL | 2.1122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04060017 | Active Recruiting |
Drug: Levoleucovorin Calcium Other: Placebo |
Autism Spectrum Disorder Language Disorders |
Rossignol Medical Center | September 22, 2020 | Phase 2 |
| NCT02839915 | Active Recruiting |
Other: Placebo Drug: Folinic Acid |
Autism Spectrum Disorder | Rossignol Medical Center | August 13, 2020 | Phase 2 |
| NCT03750786 | Active Recruiting |
Drug: Arfolitixorin Drug: Leucovorin |
Colo-rectal Cancer | Isofol Medical AB | December 18, 2018 | Phase 3 |
| NCT00082706 | Active Recruiting |
Drug: Leucovorin Drug: 5-Fluorouracil (5-FU) |
Bladder Cancer Urethral Cancer |
M.D. Anderson Cancer Center | April 23, 2003 | Phase 2 |
| NCT00217737 | Active Recruiting |
Drug: Oxaliplatin Drug: Leucovorin Calcium |
Lynch Syndrome Stage IIA Colon Cancer AJCC v7 |
National Cancer Institute (NCI) |
August 4, 2005 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA